Want to see IN:HALEOSLABS full AI Analyst Report?

SMS Lifesciences India Ltd. (HALEOSLABS) Price & Analysis

1 Followers

HALEOSLABS Stock Chart & Stats

₹1105.00

₹4.55(0.36%)

At close: Jan 08 4:00 PM EST

₹1105.00

₹4.55(0.36%)

Day’s Range― - ―

52-Week Range₹1,050.05 - ₹1,778.35

Previous CloseN/A

VolumeN/A

Average Volume (3M)154.00

Market Cap

₹4.70B

Enterprise Value₹4.99B

Total Cash (Recent Filing)₹15.71M

Total Debt (Recent Filing)₹697.87M

Price to Earnings (P/E)27.9

Beta1.03

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)48.10

Shares Outstanding3,023,287

10 Day Avg. Volume53

30 Day Avg. Volume154

Financial Highlights & Ratios

PEG Ratio-1.50

Price to Book (P/B)1.69

Price to Sales (P/S)1.08

P/FCF Ratio-15.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound (FY2026)A ~35% revenue rebound in FY2026 signals restored demand and improved order activity for API sales. Sustained top-line momentum supports better capacity utilization, enables scale benefits over months, and provides a foundation for margin recovery if cost pressures ease.

Manageable Leverage And Growing Equity BaseA moderate debt-to-equity (~0.52) and steadily growing equity provide financial flexibility to fund capex or working-capital needs. Manageable leverage reduces near-term solvency risk and supports strategic investments or customer qualification spends over the coming 2–6 months.

API-focused Business Model With Domestic And Export ReachA core API/intermediate manufacturing model with both domestic and export customers aligns with structural pharmaceutical outsourcing trends. Durable demand from formulators and the need for regulated-supply partners supports recurring revenue and long-term customer relationships.

Bears Say

Sharp Gross Margin CompressionGross margin fell sharply from ~35% to ~14% in FY2026, indicating pronounced pricing pressure or input-cost absorption. Persistent margin compression would erode operating cash flow, limit reinvestment capacity, and strain ability to fund certifications or export approvals over the medium term.

Weak Cash Conversion And Negative Free Cash FlowLow cash conversion (OCF coverage ~0.22–0.24) and a swing to materially negative free cash flow raise funding risk. If negative FCF persists, the company may need external financing for working capital or capex, increasing refinancing and dilution risk over the next several quarters.

Rising Debt Year-over-year Increases Financial RiskAn uptick in debt alongside compressed margins heightens leverage sensitivity. Higher interest or principal servicing needs reduce flexibility to absorb cyclical API demand swings and increase vulnerability to tighter credit conditions over a 2–6 month horizon.

SMS Lifesciences India Ltd. News

Haleos Labs Publishes Postal Ballot Notice, Opens SEBI-Compliant Special Window

SMS Lifesciences India Ltd. ( ($IN:HALEOSLABS) ) just unveiled an announcement. Haleos Labs Limited has notified the stock...

3M ago

HALEOSLABS FAQ

What was SMS Lifesciences India Ltd.’s price range in the past 12 months?

SMS Lifesciences India Ltd. lowest stock price was ₹1050.05 and its highest was ₹1778.35 in the past 12 months.

What is SMS Lifesciences India Ltd.’s market cap?

SMS Lifesciences India Ltd.’s market cap is ₹4.70B.

When is SMS Lifesciences India Ltd.’s upcoming earnings report date?

SMS Lifesciences India Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 26 days.

How were SMS Lifesciences India Ltd.’s earnings last quarter?

SMS Lifesciences India Ltd. released its earnings results on May 29, 2026. The company reported ₹1.44 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.44.

Is SMS Lifesciences India Ltd. overvalued?

According to Wall Street analysts SMS Lifesciences India Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SMS Lifesciences India Ltd. pay dividends?

SMS Lifesciences India Ltd. pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 0.12%. See more information on SMS Lifesciences India Ltd. dividends here

What is SMS Lifesciences India Ltd.’s EPS estimate?

SMS Lifesciences India Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SMS Lifesciences India Ltd. have?

SMS Lifesciences India Ltd. has 3,023,287 shares outstanding.

What happened to SMS Lifesciences India Ltd.’s price movement after its last earnings report?

SMS Lifesciences India Ltd. reported an EPS of ₹1.44 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.678%.

Which hedge fund is a major shareholder of SMS Lifesciences India Ltd.?

Currently, no hedge funds are holding shares in IN:HALEOSLABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SMS Lifesciences India Ltd.

Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applications, providing treatments for conditions such as ulcers, migraines, hypertension, and erectile dysfunction. Additionally, the company develops products for cancer, fungal infections, obesity, nausea, depression, parasitic infestations, various infectious diseases, gout, convulsions, viral ailments, and anesthesia. They also supply ingredients for antihistamines, diuretics, hair loss treatments, and ophthalmic preparations. A significant portion of their manufactured goods is destined for international markets. Established in 1990 and headquartered in Hyderabad, India, the firm was formerly known as SMS Lifesciences India Limited and is scheduled to officially adopt its current name, Haleos Labs Limited, in August 2025.